arrow
C

Caroline Solas

Pomeranian Medical University
H指数:30
被引数:3,287

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France

法国东南部地区使用Lenacapavir和/或Fostemsavir作为新兴疗法管理多药耐药HIV-1的实践经验

2026-09-120
OA
Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing

法匹拉韦的组织分布和抑制倍数在临床前模型中:迈向循证抗病毒药物重定位的流程

2026-07-030
OAAI
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study

长效卡博格韦和利匹韦林的国家人类免疫缺陷病毒1型感染者队列治疗药物监测:ANRS-MIE CARLAPOP研究首次结果

2025-08-010
PRE
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

优化卡博格韦尔联合 rilpivirine 长效疗法在 HIV 管理中的应用:证据、实施及未解决的问题

2025-07-012
OAAI
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns

molnupiravir对SARS-CoV-2的进一步临床前表征: 抗病毒活性决定因素和病毒基因组改变模式

HELIYON
IF3.6
2024-05-011
OAAI
Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study)
2023-09-180
OA
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
2022-08-3020
OAAI
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

硝唑尼特对SARS-CoV-2抗病毒活性的临床前评价

2022-08-019
OAAI